Medicine
Provera 2.5 mg tablet
Provera 2.5 mg tablet is a prescription medicine containing Medroxyprogesterone for oral use, marketed by Pharmacia & Upjohn, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at controlled room temperature 20° to 25°C (68° to 77°F). "Keep out of…
Key facts
- Active ingredient (INN)
- Medroxyprogesterone
- Brand
- Provera
- Strength
- 2.5 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 100 tablets
- Marketing authorisation holder
- Pharmacia & Upjohn
- Manufacturer
- Pharmacia & Upjohn
- Origin register
- US FDA, United States
- Storage
- Store at controlled room temperature 20° to 25°C (68° to 77°F). "Keep out of reach of children"
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- G03AC06 Medroxyprogesterone
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 3 September 2019
- Identifiers
- RxCUI 1000114, 1000124, 1000135 +3DailyMed set ID a586be28-96af-4fed-a13f-9b94fd4c7405NDC 0009-0065Application NDA011839
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 100 tablet in 1 bottle | 0009-0065-01 | Pharmacia & Upjohn | 3 September 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 18 June 1959 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Medroxyprogesterone 2.5 mg tablet.
Other strengths and forms of Medroxyprogesterone
Clinical summary
Medroxyprogesterone is a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. MedsAcross supplies Medroxyprogesterone for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about MedroxyprogesteroneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Provera prescribing information (Pharmacia & Upjohn) · U.S. National Library of Medicine, DailyMed
Need Provera 2.5 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.